ORGO — Organogenesis Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $669.79m
- $527.14m
- $482.04m
- 94
- 34
- 97
- 89
Annual cashflow statement for Organogenesis Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 17.2 | 94.9 | 15.5 | 4.95 | 0.861 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 7.69 | 26 | 30.7 | 26.7 | 55.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -27.8 | -37.7 | -34.1 | -18.1 | -48.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 5.47 | 62 | 24.9 | 30.9 | 14.2 |
| Capital Expenditures | -17.7 | -31.2 | -33.9 | -24.4 | -10 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -5.82 | 0 | — | — | — |
| Acquisition of Business | |||||
| Cash from Investing Activities | -23.5 | -31.2 | -33.9 | -24.4 | -10 |
| Financing Cash Flow Items | 55.6 | -1.22 | -1.26 | -0.332 | -1.18 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 42.5 | -1.04 | -2.2 | -5.5 | 27.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 24.4 | 29.7 | -11.2 | 1.05 | 31.8 |